Sunday, November 8, 2026

USD/EUR Over 1% Down In The Last 21 Sessions

USD/EUR Over 1% Down In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.94% for the last 21 sessions. At 14:11 EST on Sunday, 26 March, USD/EUR (USDEUR) is $0.93.

USD/EUR's yearly highs and lows, it's 3.892% up from its 52-week low and 11.372% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.60%, a negative 0.12%, and a positive 0.47%, respectively.

USD/EUR's highest amplitude of average volatility was 0.60% (last week), 0.56% (last month), and 0.47% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy price analysis: bounces off multi-week low, remains vulnerable below 61.8% fibo.. According to FXStreet on Friday, 24 March, "On the flip side, the daily swing low, around the 129.65 region, now seems to protect the immediate downside, below which the USD/JPY pair could fall to the 129.00 mark. ", "That said, a strong broad-based US Dollar (USD) rally lends some support to the USD/JPY pair and helps limit any further losses, at least for the time being."
  • Usd/jpy price analysis: bears poke 10-week-old support line near 130.50. According to FXStreet on Friday, 24 March, "Following that, the 130.00 round figure and multiple levels marked in February near 129.30, as well as near 128.00, could test the USD/JPY bears before directing them to the yearly low of 127.21.", "Alternatively, USD/JPY recovery can initially aim for the 50-DMA hurdle of 132.60. "
  • Usd/jpy remains heavily offered near 130.00 mark, its lowest level since February 10. According to FXStreet on Friday, 24 March, "This, in turn, is holding back bearish traders from placing fresh bets around the USD/JPY pair and helping limit the downside, at least for the time being. ", "This, along with the US bond yields, might influence the USD price dynamics and provide some impetus to the USD/JPY pair. "
  • Usd/jpy steadies near six-week low under 131.00 on mixed Japan inflation, US data eyed. According to FXStreet on Friday, 24 March, "Elsewhere, mixed US data and comments from US Treasury Secretary Janet Yellen also allow USD/JPY to lick its wounds.", "On the other hand, the US Treasury Secretary's testimony in front of the House Appropriations Financial Services Subcommittee probed the market's previous risk-on mood and allowed the USD/JPY to recover from multi-day low as she said, "China and Russia may want to develop an alternative to the US dollar," while also showing preparedness for additional deposit actions `if warranted'. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com